Immuneering’s (IMRX) Buy Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a report published on Monday,Benzinga reports. Chardan Capital currently has a $13.00 target price on the stock.

Several other research analysts have also weighed in on IMRX. Needham & Company LLC reissued a “buy” rating and set a $12.00 price target on shares of Immuneering in a research report on Friday, March 21st. Morgan Stanley cut Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th.

Immuneering Trading Down 3.0 %

IMRX stock opened at $1.64 on Monday. The firm has a 50-day moving average of $1.78 and a two-hundred day moving average of $2.00. The firm has a market capitalization of $58.85 million, a PE ratio of -0.83 and a beta of -0.32. Immuneering has a one year low of $1.00 and a one year high of $3.83.

Immuneering (NASDAQ:IMRX) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.16). On average, equities research analysts anticipate that Immuneering will post -1.86 earnings per share for the current year.

Hedge Funds Weigh In On Immuneering

A number of hedge funds have recently modified their holdings of IMRX. Southport Management L.L.C. boosted its position in Immuneering by 4.9% during the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company’s stock valued at $473,000 after purchasing an additional 10,000 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new stake in shares of Immuneering during the 4th quarter worth about $390,000. HighTower Advisors LLC lifted its holdings in shares of Immuneering by 33.7% during the 4th quarter. HighTower Advisors LLC now owns 71,360 shares of the company’s stock valued at $157,000 after buying an additional 18,000 shares during the last quarter. Bridgeway Capital Management LLC grew its stake in shares of Immuneering by 77.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock valued at $113,000 after buying an additional 22,400 shares in the last quarter. Finally, Two Sigma Investments LP grew its stake in shares of Immuneering by 25.0% in the 4th quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock valued at $111,000 after buying an additional 10,126 shares in the last quarter. 67.65% of the stock is owned by institutional investors and hedge funds.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.